Physician profile
Nimish Patel
NPI 1114119914
$1,182.86
in general payments reported to CMS, 2019-2025
13 companies · $60.95 in 2025
The $60.95 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $232 · 2021: $21.07 · 2022: $124 · 2023: $148 · 2024: $315 · 2025: $60.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $290.64 | 2020-2023 | Xarelto |
| Edwards Lifesciences Corporation | $167.19 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic USA, INC. | $167.15 | 2019 | |
| Merck Sharp & Dohme LLC | $105.00 | 2022 | |
| Biotronik INC. | $85.24 | 2024 | Amvia Edge |
| Kestra Medical Technology Services, INC. | $82.83 | 2024-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $82.49 | 2019-2024 | Camzyos |
| Teleflex LLC | $73.54 | 2019-2023 | Guideliner |
| Janssen Scientific Affairs, LLC | $68.04 | 2019 | |
| Chiesi USA, INC. | $28.73 | 2020 | |
| Pfizer INC. | $17.16 | 2024 | |
| Astellas Pharma US INC | $14.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.